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Abstract
Background: A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF).
To find out which patients specifically benefit from pirfenidone, we analyzed in an exploratory manner the data
from the phase III trial.
Methods: The patients in the phase III trial were stratified by baseline percentage predicted vital capacity (%VC),
arterial oxygen partial pressure (PaO2), and the lowest oxygen saturation by pulse oximetry (SpO2) during the 6-
minute steady-state exercise test (6MET). In the subpopulations, changes in VC and subjective symptoms (cough
and dyspnea on the Fletcher, Hugh-Jones [F, H-J] Classification scale) were evaluated in patients treated with high-
dose (1800 mg/day) pirfenidone, low-dose (1200 mg/day) pirfenidone, and placebo at week 52.
Results: Significant efficacy of pirfenidone in reducing the decline in VC could be seen in a subpopulation having
%VC ≥ 70% and SpO2 < 90% at baseline. This favorable effect was accompanied by categorical change in VC and
progression-free survival time. In the subpopulation, pirfenidone significantly suppressed cough and dyspnea.
Conclusions: IPF patients having %VC ≥ 70% and SpO2 < 90% at baseline will most likely benefit from pirfenidone
when evaluated using changes in VC (and %VC), and cough and dyspnea symptoms. This subpopulation could
expect to benefit most from pirfenidone treatment.
Trial Registration: This clinical trial was registered with the Japan Pharmaceutical Information Center (JAPIC) on
September 13th, 2005 (Registration Number: JAPICCTI-050121).
Background
Idiopathic pulmonary fibrosis (IPF) is a fatal, progressive
fibrotic lung disease with a median survival of 3-5 years
and no proven effective therapy to date [1,2]. Pirfeni-
done (5-methyl-1-phenyl-2-[1H]-pyridone; Shionogi &
Co., Ltd., Osaka, Japan; Marnac Inc., Dallas, TX, USA)
[3-7] is an antifibrotic drug for IPF which has combined
anti-inflammatory, antioxidant, and antifibrotic effects in
experimental models of pulmonary fibrosis [8-12]. A
randomized, double-blind, placebo-controlled phase II
trial of pirfenidone with 107 Japanese IPF patients
demonstrated that pirfenidone significantly reduced the
decline in vital capacity (VC) at week 36 compared to
placebo (p = 0.037) [7]. These encouraging results
prompted us to undertake a phase III clinical trial with
275 Japanese patients. In the Phase III trial, pirfenidone
showed significant reduction in the decline of VC at
week 52 (p = 0.042) and improved progression-free sur-
vival (PFS) time (p = 0.028) [13]. These Phase II and III
data led to regulatory approval of pirfenidone in Japan
for the treatment of IPF in 2008.
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international, randomized trials of pirfenidone for IPF
(CAPACITY, study 004 and study 006 with 435 and 344
IPF patients, respectively) [14]. In study 004, the decline
in percentage predicted forced vital capacity (FVC) at
week 72 was significantly reduced in pirfenidone-treated
patients compared to those treated with placebo (p =
0.001). In study 006, the difference in FVC change at
week 72 was not significant. However, the decline in %
FVC was reduced at all time points during the first year.
An analysis of pooled data from the two studies sup-
ported the treatment effect of pirfenidone on the %FVC,
PFS time, and 6-minute walk test (6MWT) distance. In
February 2011, pirfenidone was granted marketing
authorization by the European Commission for the
treatment of IPF.
Extended analyses of the phase III trial data in Japan
revealed a subpopulation of patients who benefited from
pirfenidone. Ebina et al. [15,16] examined the associa-
tion between pirfenidone efficacy (changes in VC at
week 52) and the baseline %VC, and reported that pirfe-
nidone was more effective in patients with relatively
mild impairment of lung function (%VC ≥70).
To clarify more precisely which patients specifically
benefit from pirfenidone, we examined the association
between pirfenidone efficacy and the baseline lung func-
tions including %VC, arterial oxygen partial pressure
(PaO2), and the lowest oxygen saturation in the 6-minute
steady-state exercise test (the lowest SpO2). In each sub-
group, the change in VC, PFS time, and subjective symp-
toms (cough and dyspnea on the Fletcher, Hugh-Jones
[F, H-J] Classification scale) were evaluated after high-
dose (1800 mg/day) pirfenidone, low-dose (1200 mg/day)
pirfenidone, and placebo treatment for 52 weeks.
Methods
Overall Design
The phase III trial in Japan was a multicenter, double-
blind, randomized, placebo-controlled trial. The diagno-
sis of IPF was in accordance with the American Thor-
acic Society (ATS)/European Respiratory Society (ERS)
Consensus statement [17] and the “Clinical diagnostic
criteria for idiopathic interstitial pneumonia (IIP)” (4th
edition) in Japan [18]. Patients received either high-dose
pirfenidone (1800 mg/day), low-dose pirfenidone (1200
mg/day), or placebo for 52 weeks.
The trial was conducted in accordance with the prin-
ciples laid down in the Declaration of Helsinki (2002
version). The protocol was approved by the institutional
review board at each center and the written informed
consent was obtained from all participants prior to
enrollment. The ongoing efficacy and safety results were
reviewed by the independent the Data and Safety Moni-
toring Board (DSMB).
Inclusion criteria
Eligible patients were adults (20-75 years old) with IPF
diagnosed on the basis of the above criteria and meeting
the following SpO2 criteria: 1) oxygen desaturation of
>5% difference between the resting SpO2 and the lowest
SpO2; 2) lowest SpO2 of ≥85% while breathing air.
Patients and randomization
In all, 325 patients were screened at 73 centers in Japan,
and 275 patients were randomized to one of three treat-
ment groups (i.e., the high-dose, low-dose, and placebo
groups) at a ratio of 2:1:2. Ultimately, 267 (108, 55, and
104 patients in high-dose, low-dose and placebo groups,
respectively) were evaluated for the efficacy as the full
analysis set (FAS). Eight patients were excluded for hav-
ing no post-baseline data.
Measurements
The measurements of VC, the lowest SpO2,P a O 2 at
rest, and subjective symptoms (cough and dyspnea
intensity rated using the F, H-J classification system
[19]) were defined as in our previous report [13]. The
cough severity was rated either 1 [none; no cough], 2
[mild; intermittent cough], 3 [moderate; irritating, but
not debilitating cough], and 4 [heavy; debilitating cough
characterized by shortness of breath and exhaustion].
Progression-free survival (PFS) was defined by death
and/or ≥10% decline in VC from baseline. VC was mea-
sured every 4 weeks, while the lowest SpO2 and other
pulmonary function tests were observed every 12 weeks.
In this trial, the primary endpoint was the change in
VC. As the secondary endpoints, we used: 1) PFS time
a n d2 )c h a n g ei nt h el o w e s tS p O 2 during the 6-minute
steady-state exercise test (6MET). Initially, the primary
endpoint was the lowest SpO2 during the 6MET, as in
the phase II trial [7]. Then, as explained in our previous
report [13], a decision was made to change the primary
endpoint to VC prior to breaking the code, in accor-
dance with the recommendation of the DSMB.
Statistical analysis
To identify the subpopulation that benefited most from
pirfenidone treatment, we stratified the patients from
the phase III trial using 70% of baseline %VC or 70 torr
of baseline PaO2 and 90% of baseline SpO2 as boundary
values. Namely, patients were stratified by baseline %VC
(<70 vs ≥70%) or PaO2 (<70 vs ≥70) and the lowest
SpO2 (<90 vs ≥90%). We selected these boundary values
based on the results of the phase II trial in Japan and
exploratory examination of the phase III trial by Ebina
et al. [15].
Following analyses were performed in each of the sub-
populations. Means of the changes in VC and %VC
from baseline were compared between the treated
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groups with the analysis of covariance (ANCOVA) using
the respective baseline measurements as covariates. In
the ANCOVA, the principle of the last observation car-
ried forward (LOCF) was adopted to impute missing
values. The cumulative PFS rates were estimated using
the Kaplan-Meier method and the distributions of PFS
time were compared using the log-rank test. ANCOVA
was used to compare the means of the changes in sub-
jective symptoms (i.e., cough and dyspnea scored on the
F, H-J classification scale) between groups treated with
either high- or low-dose pirfenidone or placebo. In
these exploratory analyses, the significance level of tests
was set at 0.1 (two-sided), inasmuch as 0.1 was the level
used in the phase III study [13].
Results
The phase III trial showed that pirfenidone reduced the
decline in VC at week 52 in IPF patients, and signifi-
cantly prolonged the PFS time, compared to placebo
[13]. In this exploratory analysis, patients were grouped
by baseline %VC or PaO2 at rest and the lowest SpO2 to
identify the subpopulations that benefited most from
pirfenidone treatment. Specifically, patients were strati-
fied on the basis of %VC (<70 vs ≥70), PaO2 (<70 vs
≥70), and the lowest SpO2 (<90 vs ≥90).
The changes in VC and %VC in subpopulations stratified
by baseline %VC, PaO2, and the lowest SpO2
When patients were stratified by baseline %VC (<70%,
≥70%) and the lowest SpO2 (<90, ≥90), pirfenidone
tended to be more effective in patients with baseline %
VC ≥70 and the lowest SpO2 <90 (Subgroup A) than in
the other subgroups. Namely, in Subgroup A, mean
declines of VC and %VC at week 52 (all p-values <0.1;
Table 1) and the distribution of progression-free survival
times (data not shown) were significantly different
between those treated with pirfenidone (high-dose, low-
dose, and high+low dose) and those treated with pla-
cebo. When patients were stratified by PaO2 (<70, ≥70)
and by SpO2 on exertion (<90, ≥ 90), pirfenidone tended
to be more effective in patients with PaO2 ≥70 and
SpO2 on exertion <90 (Subgroup B) than in the other
subgroups. P-values of the comparisons of mean
declines in VC (%VC) between the treatment groups
(pirfenidone high-dose, low-dose, and high+low dose)
and the placebo group were 0.151 (0.198), 0.088 (0.097)
and 0.059 (0.074), respectively (Table 2). In Subgroup B,
a similar trend was seen in progression-free survival
time (data not shown).
Incidentally, in the phase II trial in Japan, the change
in VC was categorized as “improved,”“ stable,” or “dete-
riorated” in accordance with the ATS/ERS criteria [17]
(where separation into three categories was based on
10% change in VC). The categorical change was signifi-
cantly different between the pirfenidone treatment
group and placebo group in the phase II trial but not in
the phase III trial as described in the Online Supple-
mentary Materials of our preceding paper [13]. By the
way, patients in Subgroup B met the criteria for entry
into the phase II trial, and Subgroup B was expected to
resemble Subgroup A. Therefore, it was expected that
significant differences might be seen by comparing cate-
gorical changes in Subgroup A and/or Subgroup B.
Thus, the distributions of categorical changes in VC at
week 52 were compared between pirfenidone (high- and
low-dose) and placebo groups with the Wilcoxon rank
s u mt e s ti n“Subgroup A” and “Subgroup B” of the
phase III trial. Then, changes in VC were classified as
“improved,”“ stable,” or “deteriorated” using the 10%
change criterion employed in the Phase II trial. The dif-
ferences in the distribution of categorical change in VC
Table 1 Decline in VC and %VC at week 52 in subpopulations characterized by baseline %VC and the lowest SpO2
Item Category 1
SpO2
Category 2
Baseline %VC
High-dose Group Low-dose Group Placebo Group P-value
LS mean (n) SE LS mean (n) SE LS mean (n) SE H vs P L vs P H+L vs P
Change
in VC
6MWT
SpO2≥90
%VC≥70 -0.072 (35) 0.033 -0.004 (16) 0.050 -0.090 (32) 0.035 0.7035 0.1595 0.2581
%VC<70 -0.263 (9) 0.073 -0.185 (6) 0.090 -0.225 (9) 0.073 0.7181 0.7350 0.9919
6MWT
SpO2<90
%VC≥70 -0.050 (36) 0.049 -0.016 (17) 0.071 -0.199 (36) 0.049 0.0359 0.0372 0.0131
%VC<70 -0.148 (23) 0.051 -0.181 (15) 0.062 -0.168 (26) 0.048 0.7768 0.8735 0.9539
Change
in %VC
6MWT
SpO2≥90
%VC≥70 -2.083 (35) 1.070 -0.420 (16) 1.580 -2.801 (32) 1.114 0.6438 0.2209 0.2927
%VC<70 -9.084 (9) 2.446 -7.340 (6) 2.963 -7.167 (9) 2.449 0.5902 0.9647 0.7427
6MWT
SpO2<90
%VC≥70 -1.737 (36) 1.569 -0.590 (17) 2.264 -6.080 (36) 1.568 0.0555 0.0493 0.0213
%VC<70 -4.143 (23) 1.637 -5.090 (15) 2.079 -5.669 (26) 1.567 0.5037 0.8280 0.6158
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cebo groups (p = 0.0691), low-dose and placebo groups
(p = 0.0861), and pooled (high + low) dose and placebo
groups in Subgroup A (p = 0.0295; Figure 1) but not in
“Subgroup B” (data not shown).
Temporal changes of subjective symptoms in
subpopulations
To evaluate the changes in subjective symptoms (i.e.,
cough and dyspnea) during the phase III trial, means of
the changes in cough score and dyspnea score (with F,
Table 2 Decline in VC and %VC at week 52 in subpopulations characterized by baseline PaO2 at rest and the lowest
SpO2
Item Category 1
SpO2
Category 2
PaO2
High-dose Group Low-dose Group Placebo Group P-value
LS mean (n) SE LS mean (n) SE LS mean (n) SE H vs P L vs P H+L vs P
Change
in VC
6MWT
SpO2≥90
PaO2≥70 Torr -0.115 (43) 0.032 -0.060 (22) 0.045 -0.137 (36) 0.035 0.6423 0.1766 0.2667
PaO2<70 Torr - (1) - - (0) - - (5) - - - -
6MWT
SpO2<90
PaO2≥70 Torr -0.115 (42) 0.043 -0.087 (28) 0.053 -0.199 (56) 0.038 0.1509 0.0881 0.0585
PaO2<70 Torr -0.014 (15) 0.067 -0.102 (4) 0.129 -0.135 (6) 0.105 0.34560 0.8456 0.5556
Change
in %VC
6MWT
SpO2≥90
PaO2≥70 Torr -3.486 (43) 1.013 -2.329 (22) 1.412 -4.544 (36) 1.107 0.4833 0.2200 0.2484
PaO2<70 Torr - (1) - - (0) - - (5) - - - -
6MWT
SpO2<90
PaO2≥70 Torr -3.755 (42) 1.379 -2.629 (28) 1.698 -6.124 (5) 1.199 0.1975 0.0965 0.0744
PaO2<70 Torr -0.204 (15) 2.040 -3.038 (4) 3.951 -3.964 (6) 3.229 0.3364 0.8578 0.5568
(-; not calculated.)
Figure 1 Categorical changes in VC from baseline to week 52 in Subgroup A [baseline %VC ≥ 70 and the lowest SpO2 < 90]. A) High-
dose vs Placebo groups, B) Low-dose vs Placebo groups, C) pirfenidone-treated (High + Low-dose) vs placebo groups. (The changes in VC are
rated as follows: improved, VC ≥ 10% increase; stable, VC < 10% change; worsened, VC ≥ 10% decline). The white, gray, and black areas indicate
improvement, stability, and deterioration, respectively. The p-values of Wilcoxon rank sum test are indicated on the right.
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observation time and are shown in Figures 2 and 3.
Further, the results of ANCOVA using the changes in
cough and dyspnea scores from baseline to week 52 as
responses, also are shown in Figures 2 and 3, respec-
tively. In the full analysis set (FAS), pirfenidone tended
to prevent the elevation of these scores more consis-
tently in the high-dose and low-dose groups than in the
placebo group, although the differences were not signifi-
cant. When examined in Subgroups A and B, changes in
cough and dyspnea scores showed that pirfenidone pre-
vented increase in cough (Figure 2) and dyspnea (Figure
Figure 2 Temporal changes in cough score in subpopulations. A) Full analysis set (FAS; all patients), B) Subgroup A [%VC ≥ 70 and the
lowest SpO2 < 90], and C) Subgroup B [PaO2 ≥ 70 and the lowest SpO2 < 90]. Data are shown as mean ± SE. High-dose (solid line); low dose
(dashed line); placebo (dashed line in bold). The mean changes from baseline to week 52 were compared between high (or low-dose) and
placebo groups with ANCOVA.
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FAS at week 52. In addition, the differences in dyspnea
scores seen in Subgroup A between pirfenidone (high-
and low-dose) and placebo groups were significant at
week 12 (p-values were 0.0428 and 0.0379, respectively).
The significant difference in cough score in Subgroup A
was seen between low-dose and placebo group (p =
0.0502).
Figure 3 Temporal changes in dyspnea score (F, H-J classification) in subpopulations. A) Full analysis set (FAS; all patients), B) Subgroup A
[%VC ≥ 70 and SpO2 during 6MET < 90], and C) Subgroup B [PaO2 ≥ 70 and SpO2 during 6MET < 90]. Data are shown as mean ± SE. High-
dose (solid line); low dose (dashed line); placebo (dashed line in bold). The mean changes from baseline to week 52 were compared between
high or low-dose and placebo groups with ANCOVA.
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Our exploratory analyses using changes in VC, categori-
cal changes in VC, PFS time, and scores on subjective
symptoms as outcomes suggested that pirfenidone was
more effective in patients with mild-to-moderate lung
function impairment (baseline %VC ≥ 70 and the lowest
SpO2 <9 0 ;S u b g r o u pA ) .I na d d ition, pirfenidone had
significant effects on some of these outcomes in Sub-
group B (baseline PaO2 ≥ 70 and the lowest SpO2 < 90).
In the population of patients with mild-to-moderate dis-
ease, pirfenidone is especially effective in patients with
desaturation during exercise which typically corresponds
to the lowest baseline SpO2 < 90.
To evaluate temporal changes in subjective symptoms
in the phase III trial, means of the changes in cough
and in F, H-J classification scores were calculated. In
FAS, pirfenidone tended to prevent the elevation of
these scores more consistently in high- and low-dose
groups than in the placebo group, but no significant dif-
ferences were detected. Additional analysis in the pre-
sent study, however, showed that compared to placebo,
pirfenidone significantly prevented elevation of these
scores at week 52 and significantly lowered dyspnea
score as early as week 12 especially in Subgroup A.
These results suggest that pirfenidone can be expected
to prevent worsening of subjective symptoms such as
dyspnea and exert this effect at a very early stage in the
same patient population shown to have reduced impair-
ment of respiratory functions such as VC. We addition-
ally compared the incidence of acute exacerbation
between pirfenidone and placebo groups in Subgroup A.
The incidence in the pirfenidone group (1.82% [1/55])
was lower than that in the placebo group (8.33% [3/36]),
although the difference was not statistically significant
(data not shown).
In the ‘responsive’ subgroup, i.e., patient subgroup
with baseline %VC of ≥70 and the lowest SpO2 of <90,
lung function is better preserved though oxygen satura-
tion is deteriorated. These are mutually conflicting char-
acteristics. As pulmonary fibrosis progresses at the early
stage of the disease, interstitial septa between the alveoli
and capillaries, which are the major sites of gas
exchange, become thickened and gas exchange and dif-
fusion become impaired. Hypoxemia is thought to be
caused by pulmonary-diffusion impairment and ventila-
tion-perfusion ratio mismatching. The ventilation-perfu-
sion ratio mismatching is more likely during exercise
due to dynamic change of pulmonary circulation and
increased flow, irrespective of PaO2 status at rest [20].
In this way, the thickening of the lung interstitial septa
leads to desaturation and dyspnea during exercise at an
early stage of the disease progression. The results show-
ing that pirfenidone tended to be more effective in
patients with %VC ≥70 and the lowest SpO2 <90 than in
patients with %VC <70 and the lowest SpO2 <90 (Table
1) suggest that the desaturation exhibited by the sub-
group with more preserved lung function may have
been due to developing fibrosis with inflammatory
edema and not to established fibrosis. Pirfenidone could
be more effective in treating such ‘young’ fibrosis and
therefore able to inhibit progression of fibrosis during
the early stage. Furthermore, pirfenidone, which also has
anti-inflammatory activity [3], may be effective in
improving dyspnea by reducing inflammatory edema
and vascular permeability. Above explanations are spec-
ulative, and therefore a future prospective clinical study
is necessary to confirm the better response to this drug
by this subgroup.
Recent clinical trials of drugs for IPF tend to include
mild-to-moderate cases while totally excluding severe
cases, as in the clinical trials of IFN-g [21]. This is prob-
ably because the inclusion of severe cases can bias the
evaluation of treatment effectiveness. In the phase II
trial of pirfenidone for Japanese patients [7], mean
decline in VC was 130 mL in the placebo group and 30
mL in pirfenidone-treated groups with a p-value of
0.0356 at week 36. The reduction in decline by pirfeni-
done was greater than that obtained in the phase III
trial in Japan [13]. The entry criteria of the phase II trial
included PaO2 at rest of ≥70 torr and the lowest SpO2
during 6MET of ≤9 0 % ,w h i l ec r i t e r i ao ft h ep h a s eI I I
trial were broader (i.e., 1] oxygen desaturation of >5%
difference between resting SpO2 and the lowest SpO2,
and 2] the lowest SpO2 >85% while breathing air).
These characteristics were similar in patients enrolled in
the phase II trial and in the Subgroup B patients of the
phase III trial enrolled in this study. Pirfenidone was
shown to have a more marked effect on both the
patients with the lowest SpO2 ≤ 90% in Subgroup B as
those in the phase II trial (data not shown). Possibly, the
phase II trial might have enrolled a population of
p a t i e n t sw h ow e r em o r er e s p o n s i v et ot h ed r u g .T h e
broader criteria for inclusion into the phase III trial
might have resulted in a more heterogeneous population
and more variable data.
In Japan, the severity of idiopathic interstitial pneumo-
nia (IIPs) is classified on the basis of baseline PaO2
value at rest, and categories are defined by 10-torr inter-
vals. The grade of IIPs in patients with SpO2 of < 90 on
exertion is increased by one (except for grade I) as
described in the online supplemental materials of our
previous report of the Phase III trial [13]. In the phase
III trial, patients were grouped based on severity to
identify the subpopulation that was more responsive to
pirfenidone. Pirfenidone was found to be more effective
in grade-III patients (data not shown). A more detailed
analysis revealed that the population of patients with
PaO2 ≥ 70 and < 80 included many grade-III patients
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These findings also may support the efficacy of pirfeni-
done in patients with desaturation during exercise.
Identifying those patients clinically responsive to pirfeni-
done is very important. The present analyses revealed that
pirfenidone was more effective in populations of patients
with relatively favorable baseline %VC and PaO2, especially
in those with desaturation on exertion. Since pirfenidone
was more effective in Subgroup A than in Subgroup B,
baseline %VC may be a more appropriate index than
PaO2. In addition, patients presenting desaturation during
exercise may be comparable to those complaining of dys-
pnea on exertion. For more beneficial use of pirfenidone,
the factors–baseline %VC and the presence/absence of
complaints of dyspnea on exertion–may be used to select
candidate patients. However, since responsiveness in this
study depended on the stage of the disease as determined
by respiratory function tests, these factors cannot be
regarded as indicative of a responsive phenotype but
rather as indicative of a responsive “phenostage” (coinage
by the authors). (A ‘Phenotype’ determining response to
therapy, for example to anti-cancer therapy, is generally
characterized by expression of a specific gene, whereas the
‘responsiveness’ of the subgroup identified in this study
may be due to the timing of treatment during disease pro-
gression rather than a specific gene.) A sub-analysis of
data from the CAPACITY trials [14] yielded similar
results. The FVC change at week 72 showed that a subpo-
pulation of patients given oxygen during 6MWT at base-
line responded favorably to pirfenidone [22]. To
determine whether this observation and our findings are
equivalent, a detailed sub-analysis of data from the CAPA-
CITY trials or further prospective studies will be needed.
To support the results obtained from the analyses
described in preceding sections, we used respiratory
function tests at baseline to determine the factors asso-
ciated with the efficacy of pirfenidone. Thus, we
included percentage predicted total lung capacity (%
TLC), %DLco in addition to the lowest SpO2,% V C ,a n d
PaO2. Then, we used the change in VC from baseline to
week 52 as the efficacy parameter and evaluated the
effects of the 5 function tests on this efficacy parameter
in pirfenidone and placebo groups. At first, correlation
coefficients among the 5 respiratory tests were calcu-
lated in the pirfenidone and placebo groups. The corre-
lation coefficients between %VC and %TLC were very
high in both groups (0.811 and 0.826, respectively).
Thus, we subsequently omitted %TLC from the evalua-
tion, and retained %VC since %VC behaves like VC
(which was the primary endpoint in the phase III trial)
and was considered indispensable in the additional ana-
lysis. Then, we applied a multiple regression model let-
t i n gt h ec h a n g ei nV Cs e r v ea st h er e s p o n s ev a r i a b l e
and the four respiratory function tests as explanatory
variables in the two groups (Table 3). From the Tables,
the regression coefficient of %VC in the pirfenidone
group was significant (p = 0.0018), and it was suggested
that in patients with relatively low baseline %VC, the
tendency to prevent the decline in VC was greater in
the pirfenidone group than in the placebo group.
Further, three dichotomized variables (the lowest
SpO2,% V C ,a n dP a O 2 with boundary values of 90%,
70%, and 70 torr, respectively) were used in the stratifi-
cation, and the effects of the variables on the change in
VC were evaluated with a multiple regression model. In
the pirfenidone group, the coefficients of %VC and
PaO2 were significant (p-values, 0.0002 and 0.0483,
respectively, see Table 4). In the placebo group, the
coefficients were not significant. This seems to support
the findings presented in the previous sections, namely
that the most favorable response to pirfenidone relative
to placebo was in patients with %VC ≥70% and SpO2
<90 (Subgroup A). Notably, when patients were strati-
fied using 70% as the boundary value of %VC, decline in
VC was reduced in patients with %VC ≥70 after pirfeni-
done treatment but not after placebo treatment. In addi-
tion, although the coefficient of SpO2 was not
significant, the decline of VC in patients with SpO2
<90% tended to be relatively small in the pirfenidone
group and large in the placebo group. Accordingly,
patients with %VC ≥70% and SpO2 <90 (Subgroup A)
received more benefit from pirfenidone than did other
patients. For patients with PaO2 ≥70% and <70, the
change in VC differed less between the pirfenidone and
placebo groups as indicated by the negative signs of
both regression coefficients of the dichotomized PaO2.
Therefore, it was suggested that efficacy of pirfenidone
was less clear in Subgroup B than in Subgroup A.
Limitations
Given the exploratory nature of our study, limitations
include post-hoc analysis and small sample size due to
Table 3 Effects of respiratory tests on the change in VC
in Pirfenidone and Placebo groups
Group Parameter Estimate S.E. t-value p-value
Pirfenidone Intercept -0.3543 0.7428 -0.48 0.6340
(n = 155) The lowest SpO2 0.0029 0.0091 0.32 0.7514
%VC 0.0035 0.0011 3.17 0.0018
%DLco -0.0011 0.0011 -0.97 0.3361
PaO2 -0.0025 0.0021 -1.19 0.2378
Placebo Intercept -2.0951 1.2726 -1.65 0.1029
(n = 102) The lowest SpO2 0.0217 0.0146 1.48 0.1412
%VC 0.0008 0.0017 0.49 0.6279
%DLco -0.0017 0.0017 -0.99 0.3248
PaO2 0.0003 0.0033 0.10 0.9172
(%TLC was omitted from the evaluation)
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considered preliminary and need to be confirmed in
future studies. However, the phase II and III trials in
Japan as well as the CAPACITY trials identified VC or
FVC as a promising endpoint to judge the efficacy of
treatment for IPF [14]. The baseline respiratory func-
tions used to select patients for entry into the phase II
trial are incidentally similar to those of patients bene-
fiting from drug treatment in the phase III trial. In
addition, the following limitations should be
considered.
In this study, missing values were imputed with the
LOCF method. Collard [23] as well as Swigris and Fair-
clough [24] pointed out the problems associated with
using the LOCF method. Indeed, the method is simple
but has its own deficiencies. However, there are no per-
fect imputation methods, and we explained the issues in
detail as a rejoinder to Swigris and Fairclough [25].
In this paper, we analyzed subjective symptom out-
comes or “patient-reported outcomes.” Though, the
results of analyses on these outcomes were not shown
in the original paper as pointed by Collard [23]. The
reason was that we didn’t place much value in cough
and dyspnea (F, H-J classification) as patient-reported
outcomes, since these outcomes were treated as tertiary
end-points in the phase III trial. In addition, these out-
comes were observed not retrospectively but prospec-
tively, as was described in section “Efficacy end-points”
of our previous paper [13].
Additional clinical studies are desired to confirm the
findings obtained in this study.
Conclusion
The results of these explanatory analyses identified IPF
patients having baseline %VC ≥ 70 and SpO2 <9 0 %
during 6MET as the subpopulation that benefited most
from pirfenidone treatment in terms of the changes in
VC, PFS, and subjective symptoms such as cough and
dyspnea. It is suggested that this subpopulation, espe-
cially, will benefit from pirfenidone treatment.
Abbreviations used in this paper
IPF: idiopathic pulmonary fibrosis; VC: vital capacity;
PFS: progression-free survival; SpO2:o x y g e ns a t u r a t i o n
by pulse oximetry; %DLco: % diffusing capacity of the
lung for carbon monoxide; %TLC: % predicted total
l u n gc a p a c i t y ;F A S :f u l la n a l y s i ss e t ;P F T :p u l m o n a r y
function test; 6MET: 6-minute steady-state exercise test;
ANCOVA: analysis of covariance; LOCF: last observa-
tion carried forward; ATS: American Thoracic Society;
ERS: European Respiratory Society; F: H-J, Fletcher,
Hugh-Jones; DSMB: Data and Safety Monitoring Board.
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